1: Ang ZY, Boddy M, Liu Y, Sunderland B. Stability of apomorphine in solutions containing selected antioxidant agents. Drug Des Devel Ther. 2016 Oct 3;10:3253-3265. PubMed PMID: 27757015.
2: Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 2012 Feb 1;118(3):750-60. doi: 10.1002/cncr.26336. PubMed PMID: 21751201.
3: Kuehl PJ, Stratton SP, Powell MB, Myrdal PB. Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm. 2009 Dec 1;382(1-2):104-10. doi: 10.1016/j.ijpharm.2009.08.016. PubMed PMID: 19699284; PubMed Central PMCID: PMC2783960.
4: Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther. 2007 Jul;322(1):228-35. PubMed PMID: 17412884; PubMed Central PMCID: PMC2820734.
5: Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer. 2007 Apr 15;120(8):1657-63. PubMed PMID: 17230522.
6: Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest New Drugs. 2007 Apr;25(2):107-14. PubMed PMID: 17024575.
7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851.
8: Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan;24(1):89-94. PubMed PMID: 16379038.
9: Kuehl PJ, Angersbach BS, Stratton SP, Myrdal PB. Development of an HPLC method for the analysis of Apomine in a topical cream formulation. J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80. PubMed PMID: 16181759.
10: Elmore E, Siddiqui S, Navidi M, Steele VE, Redpath JL. Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels. J Cell Biochem. 2005 Jun 1;95(3):571-88. PubMed PMID: 15786488.
11: Lowe LC, Senaratne SG, Colston KW. Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation. Biochem Biophys Res Commun. 2005 Apr 8;329(2):772-9. PubMed PMID: 15737653.
12: Bonate PL, Floret S, Bentzen C. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males. Br J Clin Pharmacol. 2004 Aug;58(2):142-55. PubMed PMID: 15255796; PubMed Central PMCID: PMC1884594.
13: Roitelman J, Masson D, Avner R, Ammon-Zufferey C, Perez A, Guyon-Gellin Y, Bentzen CL, Niesor EJ. Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. J Biol Chem. 2004 Feb 20;279(8):6465-73. PubMed PMID: 14627708.
14: Alberts DS, Hallum AV 3rd, Stratton-Custis M, Garcia DJ, Gleason-Guzman M, Salmon SE, Santabarbara P, Niesor EJ, Floret S, Bentzen CL. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res. 2001 May;7(5):1246-50. PubMed PMID: 11350890.
15: Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59. Review. PubMed PMID: 11254888.
16: Jackson B, Gee AN, Guyon-Gellin Y, Niesor E, Bentzen CL, Kerns WD, Suckling KE. Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i). Arzneimittelforschung. 2000 Apr;50(4):380-6. PubMed PMID: 10800637.
17: Flach J, Antoni I, Villemin P, Bentzen CL, Niesor EJ. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Commun. 2000 Apr 2;270(1):240-6. PubMed PMID: 10733934.

Chemical
CAS Num	126411-13-0
Chemical Formula	C28H52O7P2
Molecular Weight	562.6645
IUPAC Chemical Name	tetraisopropyl (2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethane-1,1-diyl)bis(phosphonate)
Exact Mass	562.3188
Elemental Analysis	C, 59.77; H, 9.32; O, 19.90; P, 11.01
Synonym	Apomine; APB-231-A-2; SK&F-99085; SR-45023A; SR-9223i; APB-231-A2; SK&F99085; SR45023A; SR9223i.
Solubility	Soluble in DMSO
SMILES Code	OC1=C(C(C)(C)C)C=C(CC(P(OC(C)C)(OC(C)C)=O)P(OC(C)C)(OC(C)C)=O)C=C1C(C)(C)C
Biological
Targets and Effects	HMG-CoA-reductase
Pathways	Apoptosis
Physical
Appearance	Solid powder
Purity	>98% (or refer to the Certificate of Analysis)
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition	Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shelf Life	>2 years if stored properly